Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:54454
Structure:
Synonyms:
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]et
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AIDS-111666
AIDS111666
BB_NC-1255
BCBcMAP01_000007
BPBio1_001001
BRN 4768037
BSPBio_000909
BSPBio_002337
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
C25H38O5
CCRIS 7558
CHEBI:9150
Cholestat
Coledis
Colemin
Corolin
D00434
DB00641
Denan
DivK1c_006991
DRG-0320
HSDB 7208
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
L 644128-000U
Labistatin
Lipex
Lipovas
Lodal s
Lodales
LS-46264
Medipo
Mixture Name
MK 0733
MK-0733
MK-733
MLS001304029
MLS001333077
MLS001333078
MLS002154038
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
nchembio790-comp16
Nivelipol
Pantok
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rendapid
S6196_SIGMA
Simovil
SIMVASTATIN
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:BAN:INN]
Simvastatin [USAN:INN:BAN]
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Sinvacor
Sivastin
SMR000718785
SPBio_001881
SPBio_002830
SpecPlus_000895
SPECTRUM1504236
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Synvinolin
TNP00259
Vasotenal
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
ATC-Codes:
Side-Effects:
Side-EffectFrequency
constipation0.13426316
atrial fibrillation0.057
flatulence0.050999995
abdominal pain0.044826083
endocrine disorders0.042
diabetes mellitus0.042
headache0.041736852
nausea0.03603572
infection0.032
diarrhea0.03185714
upper respiratory infection0.026157895
dyspepsia0.020000003
asthenia0.014600003
eczema0.012625001
cataract0.005666666
myalgia0.0038536591
rash0.0014054052
pruritus0.0014
gynecomastia0.0010
hepatic failure0.0010
chills0.0010
toxic epidermal necrolysis0.0010
anaphylaxis0.0010
hemolytic anemia0.0010
positive ana0.0010
erythema multiforme0.00068
vasculitis0.00054
urticaria0.00054
thrombocytopenia0.00054
lupus0.00054
malaise0.00054
photosensitivity0.00054
arthralgia0.00054
polymyalgia rheumatica0.00054
arthritis0.00054
angioedema0.00054
dermatomyositis0.00054
flushing0.00054
fever0.00054
dyspnea0.00054
eosinophilia0.00054
esr increased0.0005
vomiting0.00035
stevens - johnson syndrome0.00035
rhabdomyolysis0.00035
purpura0.00035
anemia0.00035
dizziness0.00035
hepatitis0.00035
jaundice0.00035
leukopenia0.00035
muscle cramps0.00035
pancreatitis0.00035
paresthesia0.00035
alopecia0.00035
hypersensitivity0.00035
peripheral neuropathy0.00034
anorexia0.00033
sensory disturbance0.00033
elevated alkaline phosphatase0.00033
muscle weakness0.00033
anxiety0.00033
skin erythema0.0
bronchitis0
decreased libido0
myopathy0
memory loss0
hepatic necrosis0
tremor0
nerve palsy0
chronic active hepatitis0
ophthalmoplegia0
sinusitis0
vertigo0
gastritis0
weakness0
regurgitation0
hepatoma0
cirrhosis0
swelling0
edema0
insomnia0
memory impairment0

Target

show target details
Uniprot ID:AKT1_MOUSE
Synonyms:
AKT1 kinase
C-AKT
PKB
Protein kinase B
RAC-alpha serine/threonine-protein kinase
RAC-PK-alpha
Thymoma viral proto-oncogene
EC-Numbers:2.7.11.1
Organism:Mouse
Mus musculus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

15475833
Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway.. Sebastian Wolfrum; Andreas Dendorfer; Morten Schutt; Britta Weidtmann; Angelika Heep; Klaus Tempel; Harald H Klein; Peter Dominiak; Gert Richardt (2004) Journal of cardiovascular pharmacology display abstract
Long-term pretreatment with statins reduces myocardial injury after acute ischemia and reperfusion by increasing the expression of endothelial nitric oxide synthase (eNOS). We hypothesized that statins may act rapidly enough to protect the myocardium from ischemia/reperfusion injury when given right at the beginning of the reperfusion period and tried to delineate the role of PI 3-kinase/Akt pathway in early eNOS activation. Activated simvastatin was given intravenously 3 minutes before starting the reperfusion after temporary coronary artery occlusion (CAO) in anaesthetized rats. Simvastatin significantly increased myocardial PI 3-kinase activity, AktSer473, and eNOSSer1177 phosphorylation and reduced infarct size by 42%. Infarct size reduction as well as activation of PI 3-kinase/Akt/eNOS pathway were not observed in rats co-treated with the PI 3-kinase inhibitor wortmannin. Contribution of eNOS was further delineated using the NOS inhibitor L-NAME, which could completely block cardioprotection by the statin. In summary, simvastatin acutely reduces the extent of myocardial necrosis in normocholesterolemic rats in an NO- dependent manner by activating the PI 3-kinase/Akt pathway. This is the first study demonstrating short-term cardioprotective effects of simvastatin in an in vivo model of ischemia/reperfusion.